Chronic Kidney Disease

Professional reference. Chronic kidney disease (CKD) is a persistent abnormality of kidney structure or function with implications for health. This reference is written for healthcare professionals and uses a UK-first approach, drawing primarily on NICE NG203, the KDIGO 2024 CKD guideline, the UK Kidney Association eCKD Guide and NHS information. Apply local pathways, formularies and specialist advice where these differ.

Clinical overview

CKD is not a single disease but a clinical syndrome encompassing sustained reduction in glomerular filtration, albuminuria and other markers of kidney damage. A practical definition is an abnormality of kidney structure or function present for more than three months. In adults, CKD includes an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² on at least two measurements separated by at least 90 days, or persistent markers of kidney damage even when eGFR is 60 or higher. Markers include albuminuria, renal-origin haematuria, structural or histological abnormalities, tubular electrolyte disorders and a history of kidney transplantation.

Classification should combine the cause of CKD, the G category of eGFR and the A category of albuminuria rather than relying on creatinine or eGFR alone. G categories are G1 ≥90, G2 60–89, G3a 45–59, G3b 30–44, G4 15–29 and G5 <15 mL/min/1.73 m². Albuminuria categories in UK practice are A1 <3 mg/mmol, A2 3–30 mg/mmol and A3 >30 mg/mmol urine albumin:creatinine ratio (ACR). G1 or G2 is not CKD in isolation: another marker of kidney disease is required.

The clinical importance of CKD extends beyond progression to kidney failure. Cardiovascular disease, acute kidney injury (AKI), medication toxicity, anaemia, mineral and bone disorder, electrolyte and acid-base disturbance, malnutrition and reduced quality of life become increasingly important as risk rises. Management therefore combines diagnosis of the underlying cause, estimation of progression and cardiovascular risk, kidney-protective treatment, medication stewardship, complication management and timely planning for specialist or kidney replacement care when appropriate.

Epidemiology

CKD is common and is frequently unrecognised because early disease is usually asymptomatic. Prevalence rises with age and with conditions such as diabetes, hypertension and cardiovascular disease. Population prevalence estimates vary according to the population studied, the equation used to estimate GFR, whether chronicity is confirmed and whether albuminuria is measured. A single low eGFR should therefore not automatically be interpreted as established CKD.

Risk is not distributed uniformly. Diabetes, hypertension, cardiovascular disease, previous AKI, structural urinary tract disease, multisystem inflammatory disease and inherited kidney disorders all increase the likelihood of CKD. Socioeconomic disadvantage and differences in access to prevention and long-term care can also affect burden and outcomes. Some ethnic groups experience higher rates of particular kidney diseases or kidney failure, but ethnicity should not be used as a substitute for individual assessment of cause and risk.

Most people identified with mild or moderate CKD will not progress to kidney failure. For many, cardiovascular events and competing comorbidity are more likely outcomes. This is why modern CKD assessment increasingly uses both eGFR and albuminuria, and for appropriate adults with G3a–G5 CKD uses validated kidney-failure risk prediction to inform referral and planning rather than using an eGFR threshold alone.

Aetiology

Common causes include diabetic kidney disease, hypertensive and vascular kidney disease, glomerular disease, inherited disorders such as autosomal dominant polycystic kidney disease, reflux or other congenital abnormalities, chronic obstruction and tubulointerstitial disease. Recurrent or severe AKI can leave persistent loss of kidney function and increase later CKD risk. Systemic autoimmune disease, paraproteinaemia and some infections can produce kidney injury through glomerular, vascular or interstitial mechanisms.

Medication and toxin exposure may contribute. NSAIDs can reduce renal perfusion and precipitate AKI, particularly during hypovolaemia or in combination with other haemodynamically active medicines. Lithium may cause chronic tubulointerstitial injury in susceptible patients. Other medicines can require dose adjustment as GFR falls or can accumulate and cause toxicity. A medication review should therefore form part of both assessment and follow-up.

The apparent cause should be reconsidered when the phenotype is atypical. Heavy albuminuria, active urine sediment, rapid decline, resistant hypertension, systemic symptoms, unexplained anaemia, hypercalcaemia, recurrent stones, a strong family history or unusual imaging findings may indicate a specific renal or systemic disorder that merits targeted investigation or nephrology input.

Pathophysiology

Nephron loss from many different insults can lead to adaptive hyperfiltration in remaining nephrons. Initially this helps preserve whole-kidney filtration, but sustained intraglomerular pressure and maladaptive signalling may promote proteinuria, inflammation and fibrosis. Activation of the renin–angiotensin–aldosterone system, metabolic stress, endothelial dysfunction and inflammatory pathways contribute to progression in many CKD phenotypes.

Albuminuria is both a marker of glomerular barrier injury and an important prognostic signal. Increasing ACR is associated with greater risk of CKD progression and cardiovascular events at any given eGFR. Conversely, a person with a moderately reduced eGFR and little or no albuminuria may have a different risk trajectory from someone with preserved eGFR but severe albuminuria.

As functioning nephron mass declines, homeostatic functions become progressively harder to maintain. Sodium and water handling, potassium excretion, acid excretion, erythropoietin production, vitamin D metabolism and phosphate balance may all become abnormal. The clinical manifestations of advanced CKD therefore reflect far more than reduced clearance of creatinine.

Clinical presentation

Early CKD is commonly asymptomatic and is often detected through routine blood or urine testing. Presentation may instead reflect the underlying disease: hypertension, diabetes, oedema, haematuria, urinary symptoms, recurrent infection, renal colic, systemic inflammatory features or a family history of inherited kidney disease. The absence of symptoms does not imply low risk.

With more advanced disease, non-specific symptoms may include fatigue, reduced appetite, nausea, pruritus, sleep disturbance, muscle cramps and reduced exercise tolerance. Fluid retention may produce peripheral oedema, increasing breathlessness or worsening hypertension. Nocturia can occur because concentrating ability is impaired. Anaemia may contribute to fatigue and dyspnoea.

Symptoms suggesting uraemia or severe complications require urgent assessment rather than routine CKD follow-up. These can include persistent vomiting, marked drowsiness or confusion, pericarditic chest pain, severe pruritus with systemic decline, refractory fluid overload or features of dangerous electrolyte disturbance. Clinical state, trajectory and biochemical abnormalities are more important than any single eGFR value when judging urgency.

Red flags

Urgent or accelerated assessment is appropriate when kidney function is deteriorating rapidly, AKI is suspected, potassium is dangerously elevated, pulmonary oedema or severe fluid overload is present, or there are symptoms compatible with uraemia. A substantial unexpected rise in creatinine should be approached as possible AKI until the time course and cause are clarified; chronic staging systems are intended for stable renal function.

Features suggesting potentially treatable intrinsic renal disease include visible or significant persistent haematuria with proteinuria, nephritic features, rapidly increasing albuminuria, nephrotic syndrome, systemic vasculitic symptoms, unexplained inflammatory illness or a rapid sustained fall in eGFR. Severe or difficult-to-control hypertension, particularly with deteriorating renal function, may also warrant expedited specialist assessment.

Obstruction must not be missed. New anuria or oliguria, bladder distension, bilateral hydronephrosis, a solitary functioning kidney with obstruction, or symptoms suggesting an obstructed infected urinary tract require urgent action. The threshold for imaging and specialist discussion should be lower where delay could cause irreversible loss of function.

Differential diagnosis

A low eGFR on one blood test may represent AKI, biological variation, dehydration, medication-related haemodynamic change or laboratory variation rather than CKD. Chronicity should be established from previous results or repeat testing. Creatinine-based eGFR is less reliable where creatinine generation is unusual, including very high or low muscle mass, amputation, severe malnutrition or rapidly changing renal function.

Albuminuria can be transient. Intercurrent febrile illness, urinary infection, strenuous exercise, decompensated heart failure and marked hyperglycaemia can affect urinary albumin excretion. Unexpected albuminuria should be interpreted in clinical context and confirmed according to the relevant pathway. Haematuria also has renal and urological causes; persistent haematuria may require investigation beyond CKD assessment.

Other explanations for symptoms attributed to advanced CKD should be considered. Oedema may arise from heart failure, liver disease, venous disease or hypoalbuminaemia; fatigue may reflect anaemia, endocrine disease, malignancy, infection or medication effects; and nausea or cognitive symptoms are non-specific. CKD can coexist with these conditions and may alter their management.

Assessment

Assessment begins with confirming chronicity and characterising severity. Review current and historical creatinine/eGFR, urine ACR, urinalysis and blood pressure. Document diabetes, cardiovascular disease, previous AKI, urinary tract disease, systemic disease, pregnancy potential where relevant, family history and exposure to nephrotoxic or renally cleared medicines. Consider whether the pattern fits the presumed cause.

Record both G and A categories. The combination provides substantially more prognostic information than either alone. ACR should generally be used rather than total urinary protein for initial risk stratification because albumin measurement is standardised for CKD staging and is particularly informative for diabetic and glomerular kidney disease. Marked non-albumin proteinuria can, however, suggest alternative pathology such as light-chain disease and requires appropriate investigation.

Assess cardiovascular risk and modifiable factors including smoking, weight, physical activity, diet, blood pressure, glycaemic control and lipid management. Review vaccination and sick-day or acute-illness advice where locally recommended. Discuss over-the-counter NSAID use and ensure patients know to seek advice before starting supplements or medicines that may affect renal function or potassium.

For adults with CKD G3a–G5, validated risk prediction can support personalised referral and planning. NICE recommends the 4-variable Kidney Failure Risk Equation (KFRE), using age, sex, eGFR and ACR, to estimate risk of needing kidney replacement therapy. UK Kidney Association guidance notes that a five-year kidney-failure risk above 5% is a criterion for considering specialist referral, interpreted alongside patient wishes, comorbidity and other referral indications.

Investigations

Core investigations include serum creatinine with eGFR and urine ACR. Urinalysis for blood and other abnormalities can help identify intrinsic renal or urological disease. Repeat testing should be timed according to the clinical scenario: a new unexpectedly low eGFR may need prompt repetition to exclude acute deterioration, while confirmation of stable chronic disease requires evidence persisting beyond three months.

Additional blood tests are guided by stage and suspected cause and may include full blood count, electrolytes, bicarbonate, calcium, phosphate, liver profile, HbA1c and other metabolic or immunological tests. In unexplained CKD, disproportionate anaemia, hypercalcaemia or high total protein may prompt assessment for a monoclonal gammopathy. Serology for autoimmune or infectious causes should be targeted rather than indiscriminate.

Renal ultrasound is useful where obstruction, structural disease, recurrent stones, polycystic disease, asymmetry, congenital abnormality or advanced unexplained CKD is suspected. Imaging can identify kidney size, cysts, hydronephrosis and some structural abnormalities but does not replace functional assessment. CT, MRI or vascular imaging is reserved for specific questions and should consider contrast-related and other risks.

Kidney biopsy is not required for routine diabetic or vascular CKD but can establish diagnosis and guide treatment when glomerular, interstitial or systemic disease is suspected and the result is likely to alter management. Decisions about biopsy should consider bleeding risk, kidney size, comorbidity and the clinical value of histological information.

Management

Management should be individualised to cause, G and A category, predicted progression, cardiovascular risk, frailty, comorbidity and patient goals. Core principles are treatment of the underlying disease where possible, reduction of cardiovascular and kidney-failure risk, avoidance of additional kidney injury, management of complications and preparation for advanced kidney care when indicated.

Blood-pressure control is central. Targets and medicine choice should follow current NICE guidance and be individualised for age, albuminuria, diabetes, postural symptoms and comorbidity. Renin–angiotensin system blockade with an ACE inhibitor or angiotensin receptor blocker has a particularly important role in appropriate patients with albuminuric CKD. Renal function and potassium should be checked around initiation and dose changes according to guideline recommendations. ACE inhibitors and ARBs should not routinely be combined.

SGLT2 inhibitors have become an important kidney-protective treatment for eligible people with CKD, including many with and without diabetes. Eligibility depends on the specific licensed indication and current NICE technology appraisal/guideline criteria, eGFR, albuminuria and comorbidity. Clinicians should use current product information and local formulary guidance, counsel about expected effects and adverse events, and provide appropriate acute-illness/perioperative advice. This reference intentionally does not substitute a fixed dosing table for current prescribing information.

In people with diabetes, glycaemic management should balance prevention of microvascular complications against hypoglycaemia risk as renal function declines. Some glucose-lowering medicines require renal dose adjustment or discontinuation at lower eGFR. Current diabetes and CKD guidance should be used when selecting SGLT2 inhibitors, GLP-1 receptor agonist therapy and other agents. KDIGO has announced a focused update to its 2024 CKD guideline chapter on delaying progression and managing complications to address emerging evidence, so clinicians should check for newer recommendations.

Cardiovascular prevention is integral to CKD care. Lipid-lowering therapy should follow NICE cardiovascular guidance, taking CKD into account as a high-risk state. Smoking cessation, regular physical activity within individual capability, healthy weight and a balanced diet should be encouraged. Excess dietary sodium can worsen blood pressure and fluid retention; NHS advice for people with CKD includes keeping salt intake below 6 g/day unless an individualised plan differs.

Medication stewardship is essential. Reconcile prescribed, over-the-counter and complementary medicines; check renal dosing; minimise avoidable NSAID exposure; and reassess medicines during intercurrent illness or changing renal function. Apparent nephrotoxicity should not lead to automatic permanent withdrawal of medicines with major cardiovascular or kidney benefit: the clinical context, degree of creatinine change, volume status, potassium and alternative causes should be assessed.

Dietary restriction should not be indiscriminate. Potassium, phosphate, protein and fluid advice should respond to biochemical abnormalities, stage, nutritional status and specialist assessment. Over-restriction can cause poor intake and malnutrition, especially in older or frail people. Dietitian input is valuable when advanced CKD, recurrent hyperkalaemia, hyperphosphataemia, weight loss or complex diabetes management is present.

Complications

Cardiovascular disease is a major source of morbidity and mortality in CKD. Risk rises as eGFR falls and albuminuria increases. Coronary disease, heart failure, stroke, peripheral vascular disease and arrhythmia may coexist, and CKD complicates decisions about antithrombotic therapy, imaging, intervention and drug dosing. Cardiovascular prevention should therefore not be deferred while attention focuses on kidney endpoints.

Anaemia becomes more common with declining kidney function, but other causes must be excluded. Iron deficiency, bleeding, B12 or folate deficiency, inflammation, haemolysis and marrow disease may coexist. Management of CKD-associated anaemia should follow current NICE and renal guidance, including appropriate iron assessment and specialist use of erythropoiesis-stimulating therapies where indicated.

CKD-mineral and bone disorder involves abnormalities of phosphate, calcium, parathyroid hormone and vitamin D metabolism and can contribute to bone and vascular disease. Routine management depends on CKD stage and biochemical findings. Advanced abnormalities generally warrant renal expertise; phosphate binders and vitamin D-related treatments should not be used simply because eGFR is reduced without appropriate indication and monitoring.

Hyperkalaemia may result from reduced excretion, acidosis, diabetes, tissue breakdown or medicines. Severity, ECG findings and rate of change determine urgency. Long-term management can include addressing reversible causes, dietary review, diuretic strategy and potassium-binding therapy in selected patients. Decisions about renin–angiotensin system inhibitors should balance potassium risk against their cardiovascular and kidney benefits.

Metabolic acidosis, sodium and water retention, pruritus, restless legs, sleep disturbance, sexual dysfunction, reduced appetite and malnutrition can occur in advanced CKD. Recurrent AKI episodes may accelerate decline. Psychosocial effects—including treatment burden, employment impact, anxiety and depression—should be recognised as part of comprehensive CKD care.

Prognosis

Prognosis varies widely. G and A category, underlying cause, age, cardiovascular disease, diabetes, blood pressure, prior AKI and the observed rate of eGFR change all contribute. A stable eGFR over several years carries different implications from the same eGFR accompanied by a rapid downward trajectory or severe albuminuria.

Kidney failure is not inevitable. NHS information notes that only a minority of people with CKD progress to kidney failure, while cardiovascular disease remains a major competing risk. Communication should therefore avoid presenting CKD stage as a countdown to dialysis. Absolute risk estimates and longitudinal trends are more useful for shared decisions.

KFRE can help quantify short- and medium-term kidney-failure risk in appropriate adults. Risk estimates should be interpreted with clinical judgement and should support—not replace—discussion of patient priorities, frailty, comorbidity and the likely benefits and burdens of referral or future kidney replacement therapy.

Follow-up

Follow-up frequency should reflect G and A category, cause, trajectory, treatment changes and intercurrent illness. Monitoring typically includes eGFR/creatinine, ACR, blood pressure and relevant complication blood tests. More frequent testing is appropriate after medication changes that affect renal haemodynamics or potassium, after AKI, with rapid progression, severe albuminuria or advanced CKD.

Trend data should be reviewed rather than isolated values. Confirm unexpected deterioration and consider volume depletion, infection, obstruction, medication effects, heart failure and other causes of AKI. A fall in eGFR that is substantially greater than expected warrants assessment even if the absolute eGFR remains above a traditional referral threshold.

Referral or nephrology discussion should follow NICE and local criteria. Important indications include high predicted kidney-failure risk, severe albuminuria in appropriate contexts, albuminuria with haematuria, sustained rapid decline, resistant hypertension, suspected rare or genetic disease, renal artery stenosis and complications that cannot be managed safely in primary care. Advanced CKD requires timely discussion of kidney replacement therapy and conservative kidney management according to patient goals.

For people approaching kidney failure, planning should occur early enough to allow informed choice among transplantation, haemodialysis, peritoneal dialysis and comprehensive conservative care. Preparation may include transplant assessment, vascular or peritoneal access planning, vaccination and multidisciplinary education. Decisions should be revisited as health and preferences change.

Prevention

Primary prevention focuses on control of diabetes and hypertension, cardiovascular risk reduction, smoking cessation, healthy weight, physical activity and avoidance of unnecessary nephrotoxins. People at increased risk should receive appropriate kidney testing so that albuminuria or declining eGFR is identified before complications develop.

Secondary prevention after CKD diagnosis includes kidney-protective pharmacotherapy where indicated, blood-pressure and metabolic control, prevention of recurrent AKI and attention to medication safety. Patients should know that acute vomiting, diarrhoea, fever, poor oral intake or new medicines may change renal risk and may justify prompt clinical advice.

Prevention also means avoiding diagnostic delay. Persistent albuminuria, haematuria or declining eGFR should not be attributed to ageing without appropriate assessment. Conversely, labelling an isolated borderline eGFR as CKD without confirming chronicity can cause unnecessary anxiety and inappropriate treatment. Accurate diagnosis and risk stratification are themselves preventive interventions.

Special populations and practical considerations

Older people and frailty. Reduced eGFR is common in later life, but age alone does not determine whether an abnormal result is clinically important. Albuminuria, trajectory, comorbidity, symptoms and treatment goals remain important. Creatinine-based eGFR can overestimate kidney function in people with very low muscle mass, while intensive blood-pressure or glucose treatment may cause postural symptoms, falls or hypoglycaemia. Medication burden should be reviewed regularly. Referral and kidney replacement decisions should incorporate frailty, life expectancy, likely symptom burden and the person’s priorities rather than relying on chronological age or eGFR alone.

Diabetes. Diabetes is a major cause of CKD, but not every person with diabetes and reduced eGFR has diabetic kidney disease. An atypical course—such as rapid deterioration, prominent haematuria, sudden heavy proteinuria or systemic features—should prompt consideration of another renal diagnosis. Management combines glycaemic and blood-pressure control, cardiovascular prevention and kidney-protective treatment. ACR is particularly useful because albuminuria identifies increased renal and cardiovascular risk even when eGFR remains preserved.

Heart failure and cardiorenal disease. Heart failure and CKD commonly coexist. Congestion itself can impair renal function, and a small creatinine change during effective decongestion does not necessarily mean structural kidney injury. Conversely, hypotension, sepsis, over-diuresis or nephrotoxic exposure can cause genuine AKI. Interpretation requires volume assessment, haemodynamics, trajectory and treatment context. Evidence-based heart-failure therapies should not be withheld solely because CKD is present; renal function and potassium monitoring should support safe use.

Pregnancy and reproductive health. Pregnancy changes renal physiology and creatinine interpretation, and some medicines commonly used for CKD or hypertension are unsuitable in pregnancy. People with significant CKD, proteinuria, hypertension or inherited renal disease who are planning pregnancy may benefit from pre-pregnancy counselling and specialist obstetric/renal input. Contraception, teratogenic medicines and genetic implications should be discussed where relevant. This general CKD reference should not be used as a substitute for pregnancy-specific renal guidance.

Children and young people. Paediatric CKD differs in causes, eGFR estimation, growth effects, blood-pressure interpretation and medicine dosing. Congenital anomalies and inherited disease are proportionally more important than in adults. The adult thresholds and risk tools in this page, including adult KFRE use, should not simply be transferred to children. Paediatric nephrology guidance should be used for diagnosis, monitoring and treatment.

People with a kidney transplant. A functioning transplant is itself a marker of CKD. Transplant recipients require specialist follow-up because graft function, rejection, infection, immunosuppression toxicity, malignancy risk and cardiovascular disease interact. Drug interactions are particularly important. Unexplained graft dysfunction should be discussed promptly with the transplant service rather than managed as routine non-transplant CKD.

Staging, progression and referral detail

CKD staging is most useful when the G and A categories are written together. For example, an eGFR of 50 mL/min/1.73 m² with an ACR of 35 mg/mmol is G3aA3, whereas an eGFR of 25 with an ACR of 15 is G4A2. The latter has lower filtration, while the former has more severe albuminuria; both dimensions matter. G1 and G2 require another marker of kidney damage because eGFR of 60 or above, by itself, does not establish CKD.

Progression should be assessed from repeated results over time, ideally using comparable laboratory methods and considering intercurrent illness and medication changes. A sustained decline carries more weight than a single fluctuation. When a fall is unexpectedly rapid, investigate potentially reversible causes and consider specialist discussion. Previous creatinine results from hospital admissions or other care settings can be invaluable for distinguishing chronic decline from an acute event.

Referral decisions should not be reduced to one threshold. NICE and UK Kidney Association pathways use predicted kidney-failure risk alongside features such as heavy albuminuria, albuminuria with haematuria, rapid sustained deterioration, resistant hypertension and suspected rare, genetic or renal-artery disease. A person with stable G4 disease already following an agreed conservative pathway may have different needs from a younger person with G2 disease, severe albuminuria and a rapidly progressive glomerular disorder.

Communication of stage and risk deserves care. The term “stage 3 CKD” can alarm people who have stable kidney function and a low absolute risk of kidney failure. Explain what eGFR and ACR represent, whether results are stable, what modifiable risks exist and why monitoring is recommended. Where KFRE is used, present the absolute time-limited risk and explain its purpose rather than treating the score as certainty.

Medication safety and acute illness

Renal impairment changes both pharmacokinetics and vulnerability to adverse effects. Dose adjustment may be needed because a medicine or active metabolite is renally cleared; other medicines alter renal haemodynamics or potassium without being directly nephrotoxic. Prescribing systems and product information should be checked using the patient’s current renal function and clinical context. For medicines with a narrow therapeutic index, specialist monitoring may be required.

During acute illness, the immediate question is whether the patient has developed AKI or is at risk of doing so. Vomiting, diarrhoea, sepsis, hypotension and poor intake can reduce renal perfusion. The appropriateness of temporarily withholding particular medicines is patient- and medicine-specific and should follow current local sick-day guidance. Any medicine paused during illness needs a clear plan for review and restart; unintended permanent discontinuation can deprive patients of important cardiovascular or kidney protection.

Contrast-enhanced imaging should be considered on clinical merit rather than automatically avoided in CKD. Risk depends on renal function, the presence of AKI, contrast route and dose, hydration status and competing diagnostic urgency. Follow current radiology and renal protocols. Delaying essential imaging can itself cause harm, particularly when evaluating life-threatening disease.

People with CKD frequently move between primary care, emergency departments, inpatient teams and specialist services. Accurate documentation of baseline creatinine/eGFR, CKD category, recent ACR, important renal diagnoses and medication changes reduces errors at transitions of care. After an AKI admission, ensure renal recovery and medication changes are reviewed and that ongoing CKD monitoring is arranged where indicated.

References

• NICE NG203 — Chronic kidney disease: assessment and management. UK guidance for detection, assessment, risk stratification, referral and management.
• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. International evidence-based guideline covering evaluation, classification, risk and management.
• UK Kidney Association eCKD Guide. UK professional guidance on CKD staging, KFRE, referral and practical management.
• NHS — Chronic kidney disease. UK overview of symptoms, diagnosis, treatment and living with CKD.

Editorial note: This reference supports professional clinical decision-making and does not replace patient-specific assessment, current prescribing information, local renal pathways or specialist advice. Guidance and medicine indications change; verify time-sensitive treatment decisions against current NICE, KDIGO, UK Kidney Association and local formulary sources.